Evolus Inc. (EOLS)

14.78 +0.04 (+0.271%)

IEX Real-Time Price

November 16, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 14.74

Price Open 14.74

Volume: 441,536

Avg Volume: 360,133

Market Cap: 403.12M

P/E Ratio -16.8

52 Wk Range 6.75-39.5



EOLS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
26.56M
1.15M
3.22
4.34%

2018-09-28
26.57M
1.07M
2.69
4.02%

2018-09-14
26.57M
766,628
2.08
2.89%

2018-08-31
26.57M
790,297
1.81
2.97%




EOLS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-05
Q3 2018
AMC
-0.51 (1)
-0.48
0.03

2018-08-02
Q2 2018
BTO
-0.29 (1)
-0.34
-0.05

2018-05-10
Q1 2018
N/A
-0.36 (1)
-0.34
-0.05

2018-03-29
Q4 2017
N/A
0.00 (0)
-0.34
-0.05

News

Evolus, Inc. (EOLS) CEO David Moatazedi on Q3 2018 Results - Earnings Call Transcript (2018-11-05 19:48 SeekingAlpha)

Evolus, Inc. (EOLS) Q3 2018 Earnings Conference Call November 5, 2018 16:30 ET Executives Ashwin Agarwal - Vice President Finance, Investor Relations and Treasury David Moatazedi - President and Chief Executive Officer Lauren Silvernail - Chief Financial Officer and EVP Corporateā€¦

 


Statistics

Shares Outstanding: 27.27M

Top 15 Institution Percent: 15.10

Price To Sales: N/A

Price To Book: 3.92

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -22.85

Return On Equity: -75.50

Profit Margin: N/A

Price History

Beta: 8.66

50-day Moving Avg: 16.75

200-day Moving Avg: 17.35

YTD Change: 28.17

5-day Change: -3.34

1-month Change: 12.09

3-month Change: -23.03

6-month Change: 0.61

1-year Change: 28.17

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Evolus Inc.

Exchange: NASDAQ Global Market

Industry: Drug Manufacturers

Sector: Healthcare

Website: https://www.evolus.com

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.